Media Contact: Shantell Kirkendoll 734-764-2220

University of Michigan announces first implant of new recapturable heart valve

Evolut R is the first-and-only recapturable and repositionable device available in the U.S.

ANN ARBOR, Mich. -- Now offering the latest, cutting edge heart valve replacement technology, the University of Michigan Frankel Cardiovascular Center announced its first implant of a newly approved recapturable heart valve.

The first-atnd-only recapturable and repositionable device available in the United States, the CoreValve Evolut R System is approved for transcatheter aortic valve replacement.

The U-M is the first Michigan hospital to offer the device which, once in place, expands to take over the diseased valve’s function to enable oxygen-rich blood to flow efficiently out of the heart.

Cardiac surgeon G. Michael Deeb, M.D., and interventional cardiologists P. Michael Grossman, M.D., and Daniel Menees, M.D., successfully completed the procedure today.

With the ability to recapture and reposition the valve during deployment, the system represents the TAVR platform of the future.

The University of Michigan has one of the highest volume TAVR programs in the country, and is leading the treatment transformation to offer minimally invasive procedures for people too old, frail or at high surgical risk for open heart surgery.  

Control during deployment

The EvolutR System was recently approved by the FDA for transcatheter aortic valve replacement in severe aortic stenosis patients who are at high or extreme risk for surgery.

Evolut R device

Aortic stenosis is a common, age-related heart problem caused by narrowing of the heart’s aortic valve. Untreated, aortic valve stenosis can lead to serious heart problems including heart failure and even death.

The CoreValve Evolut R System is a next-generation transcatheter aortic valve from Medtronic that is designed to help improve positioning accuracy and control during transcatheter aortic valve replacement procedures.

The U-M was part of a select group of hospitals to test the device during clinical trials and is one of the first to use it now that it is commercially available in the U.S.

About the U-M Frankel Cardiovascular Center Structural Heart Program

The University of Michigan is a leader in the quest for new options for structural heart repairs. It is a destination for treatment of valve disease and specialists bring experience and a culture of collaboration to the U-M’s pursuit of cardiovascular innovations.

To make an appointment to discuss whether you are a candidate for a heart valve replacement, call the University of Michigan Cardiovascular Center at 888-287-1082 or email us at CVCCallCtr@med.umich.edu.

 

NOTICE: Except where otherwise noted, all articles are published under a Creative Commons Attribution 3.0 license. You are free to copy, distribute, adapt, transmit, or make commercial use of this work as long as you attribute Michigan Medicine as the original creator and include a link to this article.

Media Inquiries:  734-764-2220 8 a.m.-5 p.m. ET 

734-936-4000 after hours, weekends, and holidays (ask for the PR person on call)  umhsmedia@umich.edu for embargoed news, videos & more